LENALIDOMIDE OR BORTEZOMIB FOR THE TREATMENT OF RELAPSED/REFRACTORY MULTIPLE MYELOMA (MM): A COMPARATIVE EFFECTIVENESS ANALYSIS USING INDIRECT STATISTICAL TECHNIQUES

被引：0
|
作者：
Kaura, S. [1 ]
Dranitsaris, G. [2 ]
机构：
[1] Celgene Corp, Summit, NJ USA
[2] Augmentium Pharma Consulting, Toronto, ON, Canada
来源：
VALUE IN HEALTH | 2012年 / 15卷 / 07期
关键词：
D O I：
10.1016/j.jval.2012.08.1727
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A508 / A509
页数：2
相关论文
共 50 条
  • [21] Canadian Cost-Effectiveness Analysis of Bortezomib in Relapsed or Refractory Multiple Myeloma Patients
    Yoong, K.
    Attard, C.
    Grima, D.
    Jivraj, F.
    Reece, D.
    CANADIAN JOURNAL OF HOSPITAL PHARMACY, 2007, 60 : 65 - 65
  • [22] Cost-effectiveness of bortezomib (VELCADE) for relapsed and refractory multiple myeloma
    Bagust, A
    Haycox, A
    Mujica-Mota, R
    Dhawan, R
    Dubois, D
    VALUE IN HEALTH, 2004, 7 (06) : 670 - 670
  • [23] THE COST-EFFECTIVENESS OF BORTEZOMIB FOR RELAPSED/REFRACTORY MULTIPLE MYELOMA IN SWEDEN
    Rickert, J. B.
    Hornberger, J.
    Dhawan, R.
    Liwing, J.
    Aschan, J.
    Lothgren, M.
    VALUE IN HEALTH, 2009, 12 (03) : A45 - A45
  • [24] Lenalidomide (Revlimid), bortezomib (Velcade) and dexamethasone for heavily pretreated relapsed or refractory multiple myeloma
    Jimenez-Zepeda, Victor H.
    Reece, Donna E.
    Trudel, Suzanne
    Chen, Christine
    Tiedemann, Rodger
    Kukreti, Vishal
    LEUKEMIA & LYMPHOMA, 2013, 54 (03) : 555 - 560
  • [25] NICE guidance on pomalidomide for relapsed and refractory multiple myeloma previously treated with lenalidomide and bortezomib
    Burke, Martyn J.
    George, Elisabeth
    Adler, Amanda I.
    LANCET ONCOLOGY, 2015, 16 (05): : 492 - 493
  • [26] Comparative effectiveness of lenalidomide/dexamethasone-based triplet regimens for treatment of relapsed and/or refractory multiple myeloma in the United States
    Sanchez, Larysa
    Chari, Ajai
    Cheng, Mu
    Cherepanov, Dasha
    DerSarkissian, Maral
    Stull, Dawn Marie
    Huang, Fei
    Hilts, Annalise
    Chun, Justin
    Duh, Mei Sheng
    Ailawadhi, Sikander
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S187 - S187
  • [27] IMPACT OF NUMBER OF PREVIOUS TREATMENT LINES AND PRE-TREATMENT WITH BORTEZOMIB OR LENALIDOMIDE ON EFFICACY OF BORTEZOMIB-BENDAMUSTINE-DEXAMETHASONE (BBD) IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (MM)
    Ludwig, H.
    Kasparu, H.
    Leitgeb, C.
    Greil, R.
    Rauch, E.
    Linkesch, W.
    Zojer, N.
    Pour, L.
    Fillitz, M.
    Adam, Z.
    ANNALS OF ONCOLOGY, 2012, 23 : 348 - 349
  • [28] THE COST-EFFECTIVENESS OF LENALIDOMIDE PLUS DEXAMETHASONE FOR THE TREATMENT OF RELAPSED OR REFRACTORY MULTIPLE MYELOMA IN CHINA
    Lu, J.
    Hu, S.
    Xu, P.
    Feng, Y.
    HAEMATOLOGICA, 2017, 102 : 602 - 602
  • [29] Lenalidomide, bortezomib, and dexamethasone (Rev/Vel/Dex) in patients with relapsed or relapsed/refractory multiple myeloma (MM): Preliminary results of a phase II study
    Richardson, Paul
    Jagannath, Sundaf
    Raje, Noopur
    Jakubowiak, Andrzej
    Lonial, Sagar
    Ghobrial, Irene
    Schlossman, Robert
    Mazumder, Amitabha
    Munshi, Nikhil
    Colson, Kathleen
    McKenney, Mary
    Farrell, Melissa
    Lunde, Laura
    Giove, Lawrence
    Kaster, Sarah
    Mitsiades, Constantine
    Hideshima, Teru
    Knight, Robert
    Esseltine, Dixie-Lee
    Anderson, Kenneth
    BLOOD, 2007, 110 (11) : 797A - 797A
  • [30] Phase I study of once weekly treatment with bortezomib in combination with lenalidomide and dexamethasone for relapsed or refractory multiple myeloma
    Haruhito Totani
    Masaki Ri
    Chie Kato
    Takahiro Nakashima
    Nana Suzuki
    Shinya Hagiwara
    Takashi Kanamori
    Satsuki Murakami
    Arisa Masuda
    Shiori Kinoshita
    Takashi Yoshida
    Tomoko Narita
    Asahi Ito
    Shigeru Kusumoto
    Takashi Ishida
    Hirokazu Komatsu
    Shinsuke Iida
    International Journal of Hematology, 2016, 103 : 316 - 321
12345